CD8A and melanoma: Yang et al. found that avasimibe improves CD8+ T cell receptor clustering and immune synapse formation in melanoma by targeting ACAT1, which increases CD8+ T cell plasma membrane cholesterol levels, thereby enhancing CD8+ T cell-mediated antitumor immunity 117.